What is Arcascope?
Founded in 2020 and headquartered in Chantilly, Virginia, Arcascope operates at the vanguard of healthcare technology. The company specializes in the development of sophisticated digital tools designed to monitor and modulate circadian rhythms, a fundamental biological process that dictates sleep-wake cycles and metabolic health. By leveraging proprietary algorithms and data-driven insights, Arcascope addresses the systemic health challenges associated with circadian misalignment, positioning itself as a key player in the burgeoning field of personalized medicine and preventative health management. Their market position is bolstered by a unique focus on translating complex biological data into actionable clinical outcomes, effectively bridging the gap between academic research and scalable enterprise-level health solutions.
How much funding has Arcascope raised?
Arcascope has raised a total of $2.9M across 1 funding round:
Angel/Seed
$2.9M
Angel/Seed (2022): $2.9M with participation from Inception Health, Inflect Health, New Dominion Angels, AIoT Health, and Supermoon Capital
Key Investors in Arcascope
New Dominion Angels
New Dominion Angels is a Washington, DC area investors group made up of entrepreneurs, operators, and executives who focus on backing early-stage startups that are addressing complex problems in large and often overlooked markets.
AIoT Health
AioT Health is a healthcare-focused syndicate fund specializing in the application of deep technology and machine learning to enhance healthcare outcomes and deliver personalized medicine.
Supermoon Capital
Supermoon Capital is a venture capital platform focused on supporting visionary founders who are innovating in the field of sleep and related categories to enhance healthy sleep.
What's next for Arcascope?
With this latest round of financing, Arcascope is well-positioned to transition from its foundational development phase into a period of aggressive commercial scaling. The strategic roadmap likely involves expanding its clinical validation studies and enhancing its software-as-a-service (SaaS) platform to better serve enterprise healthcare providers. By integrating its circadian rhythm technology into broader health management ecosystems, Arcascope aims to standardize the role of biological timing in chronic disease management. As the company continues to refine its technological stack, it remains focused on securing further partnerships that will facilitate the widespread adoption of its solutions, ultimately aiming to redefine the standard of care for sleep-related health and metabolic wellness on a global scale.
See full Arcascope company page
